^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ovarian Cancer

    Related cancers:
    19h
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS
    21h
    Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, CanariaBio Inc. | Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Apr 2024 --> Oct 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • OvaRex (oregovomab)
    22h
    TSL-B2276-1-01: A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=19, Completed, Tasly Pharmaceutical Group Co., Ltd | Recruiting --> Completed | N=132 --> 19 | Trial completion date: Dec 2027 --> Dec 2025 | Trial primary completion date: Dec 2026 --> Jun 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    luveltamab tazevibulin (STRO-002)
    1d
    FRAPPE: Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Trial completion date: Jul 2027 --> Jun 2028 | Trial primary completion date: Jul 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab)
    1d
    ProphyloCHIP: Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients (clinicaltrials.gov)
    P3, N=150, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    1d
    Squamous cell carcinoma arising within a mature cystic teratoma of the ovary in a postmenopausal woman: A case report and literature review. (PubMed, Case Rep Womens Health)
    Squamous cell carcinoma arising in a mature cystic teratoma represents a rare but clinically significant form of malignant transformation. This case underscores the importance of considering malignancy in postmenopausal women with large or symptomatic ovarian dermoid cysts and highlights the role of comprehensive histopathological evaluation in establishing an accurate diagnosis and guiding optimal management.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    1d
    A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer. (PubMed, Device)
    Negative pressure applied via the port enabled longitudinal sampling of peritoneal fluid without additional surgical intervention. By reducing procedural burden and improving adaptability, the implant can help increase patient retention and therapeutic efficacy in ovarian cancer and other intra-abdominal cancers.
    Journal
    |
    IL15 (Interleukin 15)
    1d
    Total Saponins from Aralia armata (Wall.) Seem to Act via the Wnt/ β-Catenin Signaling Pathway: Network Pharmacology and Experimental Validation. (PubMed, Comb Chem High Throughput Screen)
    AAS exerts anti-ovarian cancer effects by impeding β-catenin nuclear translocation through inhibition of the Wnt pathway, resulting in coordinated downregulation of oncogenic effectors and dual suppression of proliferation and metastasis. Furthermore, this mechanism effectively induces apoptosis and cell cycle arrest in SKOV3 cells, highlighting its multifaceted antitumor potential.
    Journal
    |
    CCND1 (Cyclin D1) • ANXA5 (Annexin A5)
    1d
    Grouper deubiquitinating enzyme ovarian tumor domain-containing protein 5 (OTUD5) stabilizes stimulator of interferon genes (STING) via the autophagy-lysosomal pathway to modulate antiviral innate immunity in fish. (PubMed, Int J Biol Macromol)
    These findings uncover a unique regulatory axis where EcOTUD5 functions as a molecular switch, differentially controlling DNA and RNA virus replication through STING stabilization and non-enzymatic mechanisms. This work provides critical insights into the role of deubiquitinases in innate immune signaling and highlights the complexity of host-virus interactions in aquatic species.
    Journal
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    1d
    GLT8D2-mediated PD-L1 N-glycosylation promotes tumor immune evasion in ovarian cancer peritoneal metastasis. (PubMed, Cancer Lett)
    Hypoxia-inducible factor HIF-1α was identified as a direct transcriptional activator of GLT8D2. Our findings highlight GLT8D2 as a key regulator of metastasis and immune evasion in OC, offering a potential strategy to improve prognosis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
    2d
    In Silico Multi-omics Analyses of Kinesin Family Member 15 in Pan-Cancer and Validation in Tissue Microarray. (PubMed, Curr Cancer Drug Targets)
    KIF15 may serve as a potential biomarker and oncogenic factor in multiple cancer types.
    Journal • Pan tumor
    |
    KIF15 (Kinesin Family Member 15)
    2d
    Comparative Analysis of Homologous Recombination Repair Status Across Gynecologic and Breast Cancers in Chinese Populations. (PubMed, Curr Cancer Drug Targets)
    The mutational patterns affecting homologous recombination repair differ across gynecologic and breast cancers. Further research into cancer-specific HRD mechanisms is warranted.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency) • JAK2 (Janus kinase 2) • PALB2 (Partner and localizer of BRCA2) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • BRCA (Breast cancer early onset) • EPHA5 (EPH Receptor A5)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • PIK3CA mutation • HRD • PALB2 mutation • BRCA mutation